mAb 58
An anti-SARS-CoV-2 monoclonal antibody.
General information
mAb 58 is a monoclonal antibody neutralizing SARS-CoV-2 (Supasa et al., 2021). It has been identified in a B cell of a COVID-19 convalescent patient (Dejnirattisai et al., 2021). mAb 58 neutralizes Omicron variant in vitro (Dejnirattisai et al., 2022). Its capacity to neutralize the Delta variant is low, however (Dejnirattisai et al., 2022; Liu et al., 2021). Weaker neutralization has been also observed in the case of the Beta variant (Zhou et al., 2021).
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses
Spike protein ACE2 RNA DNA Spike variant Crystallization Biophysical assay Protein factor In vitro Antibody Mixed substance |
sera from vaccinated or convalescent individuals; VeroE6/TMPRSS2 cells; SARS-CoV-2 (various strains) | 41.58 | Neutralizes Omicron variant in vitro. |
Jan/04/2022 |
|
Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera
Spike protein Spike variant Crystallization Protein factor In vitro Mechanism Antibody |
in vitro biophysical assay; crystallization; sera of COVID-19 convalescent patients or vaccinated adults; Vero cells; SARS-CoV-2 (SARS-CoV-2/human/AUS/VIC01/2020 and SAR-CoV-2/B.1.1.7) | 41.58 | Neutralizes SARS-CoV-2 (including the Alpha variant) in vitro. |
Feb/18/2021 |
|
The antigenic anatomy of SARS-CoV-2 receptor binding domain
Spike protein Cryo-EM Crystallization Novel compound Protein factor In vitro Mechanism Antibody |
in vitro biophysical assay; crystallization; cryo-EM; sera of COVID-19 convalescent patients; Vero cells; K18-hACE C57BL/6J mice; SARS-CoV-2 (2019n-CoV/USA_WA1/2020 and SARS-CoV-2/human/AUS/VIC01/2020) | 41.58 | Bound RBD and neutralized SARS-CoV-2 in vitro. |
Feb/18/2021 |
|
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera
Spike protein RNA DNA Spike variant Biophysical assay Protein factor In vitro Antibody Mixed substance |
in vitro biophysical assay; plasma of COVID-19 (Beta strain) convalescent patients or vaccinated adults; Vero cells; SARS-CoV-2 (SARS-CoV-2/human/AUS/VIC01/2020 and SARS-CoV-2/B.1.351) | 41.58 | Although binding to the beta version of SARS-CoV-2 RBD is weaker compared to the wild type viral strain, the antibody neutralizes the virus in vitro. |
Feb/23/2021 |
|
Antibody evasion by the P.1 strain of SARS-CoV-2
Spike protein RNA DNA Spike variant Crystallization Biophysical assay Protein factor In vitro Antibody Mixed substance |
in vitro biophysical assay; crystallization; sera of COVID-19 convalescent patients and vaccinated adults; Vero cells; SARS-CoV-2 (Victoria, Alpha, Beta, and Gamma) | 41.58 | Neutralized all of the SARS-CoV-2 strains tested in vitro. The antibody was less potent in Gamma strain neutralization, however. |
Mar/30/2021 |
|
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum
Spike protein RNA DNA Spike variant Crystallization Biophysical assay Protein factor In vitro Antibody Mixed substance |
in vitro biophysical assay; crystallization; sera of COVID-19 convalescent patients and vaccinated adults; Vero cells; HEK293T/17-hACE2 cells; SARS-CoV-2 (Victoria, Alpha, Beta, and Delta); (HIV-1) SARS-CoV-2 Spike-pseudotyped virus (various variants) | 41.58 | The antibody neutralized the Delta variant of SARS-CoV-2 in vitro. |
Jun/17/2021 |
